RS65707B1 - Pangenotipska sredstva protiv virusa influence i načini upotrebe istih - Google Patents
Pangenotipska sredstva protiv virusa influence i načini upotrebe istihInfo
- Publication number
- RS65707B1 RS65707B1 RS20240693A RSP20240693A RS65707B1 RS 65707 B1 RS65707 B1 RS 65707B1 RS 20240693 A RS20240693 A RS 20240693A RS P20240693 A RSP20240693 A RS P20240693A RS 65707 B1 RS65707 B1 RS 65707B1
- Authority
- RS
- Serbia
- Prior art keywords
- oligonucleotide
- virus
- psl2
- lna
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662302548P | 2016-03-02 | 2016-03-02 | |
| EP20208373.9A EP3800257B1 (en) | 2016-03-02 | 2017-03-01 | Pan-genotypic agents against influenza virus and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65707B1 true RS65707B1 (sr) | 2024-08-30 |
Family
ID=59743201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240693A RS65707B1 (sr) | 2016-03-02 | 2017-03-01 | Pangenotipska sredstva protiv virusa influence i načini upotrebe istih |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10597658B2 (https=) |
| EP (3) | EP3800257B1 (https=) |
| JP (3) | JP7536272B2 (https=) |
| CN (1) | CN108778344A (https=) |
| CA (1) | CA3014776A1 (https=) |
| DK (1) | DK3800257T3 (https=) |
| ES (1) | ES2981765T3 (https=) |
| FI (1) | FI3800257T3 (https=) |
| HR (1) | HRP20240765T1 (https=) |
| HU (1) | HUE066977T2 (https=) |
| LT (1) | LT3800257T (https=) |
| PL (1) | PL3800257T3 (https=) |
| PT (1) | PT3800257T (https=) |
| RS (1) | RS65707B1 (https=) |
| SI (1) | SI3800257T1 (https=) |
| SM (1) | SMT202400253T1 (https=) |
| WO (1) | WO2017151795A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021201996A1 (en) * | 2020-02-14 | 2021-10-07 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against respiratory viruses and methods of using the same |
| US12522827B2 (en) | 2016-03-02 | 2026-01-13 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
| US11339392B2 (en) | 2016-03-02 | 2022-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Pan-genotypic agents against influenza virus and methods of using the same |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT69956A (en) * | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| AU2006235364A1 (en) * | 2005-04-08 | 2006-10-19 | Marina Biotech, Inc. | RNAi therapeutic for respiratory virus infection |
| EP1937066A4 (en) * | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
| WO2007084359A2 (en) * | 2006-01-17 | 2007-07-26 | Oligos Etc., Inc. | Compositions and methods for the treatment of influenza infection |
| CN100562342C (zh) * | 2006-01-17 | 2009-11-25 | 奥林格斯技术有限公司 | 防治流感病毒感染的寡核苷酸药物 |
| CA2666657A1 (en) * | 2006-10-18 | 2008-04-24 | Nastech Pharmaceutical Company Inc. | Nicked or gapped nucleic acid molecules and uses thereof |
| US20090042823A1 (en) | 2007-08-10 | 2009-02-12 | Mdrna, Inc. | Uses of broad spectrum rnai therapeutics against influenza |
| CA2729757A1 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| AU2009310557B2 (en) * | 2008-10-27 | 2014-09-11 | Academisch Ziekenhuis Leiden | Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA |
| EP2499248B1 (en) | 2009-11-13 | 2017-01-04 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| EP2519633B1 (en) * | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
| CA2800281C (en) * | 2010-06-01 | 2021-01-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases |
-
2017
- 2017-03-01 EP EP20208373.9A patent/EP3800257B1/en active Active
- 2017-03-01 RS RS20240693A patent/RS65707B1/sr unknown
- 2017-03-01 FI FIEP20208373.9T patent/FI3800257T3/fi active
- 2017-03-01 EP EP24159464.7A patent/EP4389221A3/en active Pending
- 2017-03-01 CN CN201780014078.0A patent/CN108778344A/zh active Pending
- 2017-03-01 CA CA3014776A patent/CA3014776A1/en active Pending
- 2017-03-01 US US16/081,818 patent/US10597658B2/en active Active
- 2017-03-01 SI SI201731528T patent/SI3800257T1/sl unknown
- 2017-03-01 SM SM20240253T patent/SMT202400253T1/it unknown
- 2017-03-01 HU HUE20208373A patent/HUE066977T2/hu unknown
- 2017-03-01 EP EP17760733.0A patent/EP3423107A4/en not_active Withdrawn
- 2017-03-01 ES ES20208373T patent/ES2981765T3/es active Active
- 2017-03-01 PT PT202083739T patent/PT3800257T/pt unknown
- 2017-03-01 LT LTEP20208373.9T patent/LT3800257T/lt unknown
- 2017-03-01 DK DK20208373.9T patent/DK3800257T3/da active
- 2017-03-01 JP JP2018543209A patent/JP7536272B2/ja active Active
- 2017-03-01 WO PCT/US2017/020241 patent/WO2017151795A1/en not_active Ceased
- 2017-03-01 PL PL20208373.9T patent/PL3800257T3/pl unknown
- 2017-03-01 HR HRP20240765TT patent/HRP20240765T1/hr unknown
-
2022
- 2022-10-07 JP JP2022162516A patent/JP2022176378A/ja not_active Withdrawn
-
2025
- 2025-04-02 JP JP2025061328A patent/JP2025096365A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3800257T3 (pl) | 2024-09-16 |
| DK3800257T3 (da) | 2024-06-24 |
| HRP20240765T1 (hr) | 2024-09-13 |
| EP3423107A4 (en) | 2020-01-15 |
| JP2025096365A (ja) | 2025-06-26 |
| SMT202400253T1 (it) | 2024-09-16 |
| US10597658B2 (en) | 2020-03-24 |
| JP2022176378A (ja) | 2022-11-25 |
| WO2017151795A1 (en) | 2017-09-08 |
| EP3800257A1 (en) | 2021-04-07 |
| EP4389221A3 (en) | 2024-11-20 |
| LT3800257T (lt) | 2024-07-25 |
| HUE066977T2 (hu) | 2024-09-28 |
| JP2019511471A (ja) | 2019-04-25 |
| EP4389221A2 (en) | 2024-06-26 |
| CA3014776A1 (en) | 2017-09-08 |
| JP7536272B2 (ja) | 2024-08-20 |
| US20190136242A1 (en) | 2019-05-09 |
| ES2981765T3 (es) | 2024-10-10 |
| EP3423107A1 (en) | 2019-01-09 |
| PT3800257T (pt) | 2024-06-26 |
| EP3800257B1 (en) | 2024-05-01 |
| FI3800257T3 (fi) | 2024-06-19 |
| SI3800257T1 (sl) | 2025-04-30 |
| CN108778344A (zh) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Steinhauer et al. | Genetics of influenza viruses | |
| Suarez et al. | Multiple alignment comparison of the non-structural genes of influenza A viruses | |
| Naffakh et al. | Host restriction of avian influenza viruses at the level of the ribonucleoproteins | |
| JP2025096365A (ja) | インフルエンザウイルスに対する汎遺伝子型薬剤及びその使用方法 | |
| Szabat et al. | RNA secondary structure as a first step for rational design of the oligonucleotides towards inhibition of influenza a virus replication | |
| Meng et al. | Unexpected complexity in the interference activity of a cloned influenza defective interfering RNA | |
| Johnson et al. | Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs | |
| WO2021201996A1 (en) | Pan-genotypic agents against respiratory viruses and methods of using the same | |
| Chiang et al. | Mutations at alternative 5′ splice sites of M1 mRNA negatively affect influenza A virus viability and growth rate | |
| US12522827B2 (en) | Pan-genotypic agents against influenza virus and methods of using the same | |
| Giannecchini et al. | Oligonucleotides derived from the packaging signal at the 5′ end of the viral PB2 segment specifically inhibit influenza virus in vitro | |
| US12618063B2 (en) | Pan-genotypic agents against influenza virus and methods of using the same | |
| US20240425852A1 (en) | Pan-Genotypic Agents Against Influenza Virus and Methods of Using the Same | |
| HK40113249A (en) | Pan-genotypic agents against influenza virus and methods of using the same | |
| Giannecchini et al. | Packaging signals in the 5′-ends of influenza virus PA, PB1, and PB2 genes as potential targets to develop nucleic-acid based antiviral molecules | |
| EP4464779A2 (en) | Pan-genotypic agents against respiratory viruses and methods of using the same | |
| HK40118855A (en) | Pan-genotypic agents against respiratory viruses and methods of using the same | |
| AU2024341512A1 (en) | Agents against respiratory viruses and methods of using the same | |
| HK1262033A1 (en) | Pan-genotypic agents against influenza virus and methods of using the same | |
| Hagey et al. | Identification and targeting of a pan-genotypic influenza A virus RNA structure that mediates packaging and disease | |
| HK40091735A (zh) | 抗呼吸道病毒的泛基因型药剂及其使用方法 | |
| US11046958B2 (en) | Antisense oligonucleotides that inhibit influenza virus replication and uses thereof | |
| Hauck | No escape mutants and decreased variability of viral quasispecies after immunization against long alpha helix of pandemic H1N1 in a mouse model study |